{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:12:21Z","timestamp":1782450741935,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["15037"],"award-info":[{"award-number":["15037"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["29685"],"award-info":[{"award-number":["29685"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015570","name":"Blood Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejoncologynursing.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Oncology Nursing"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejon.2023.102421","type":"journal-article","created":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T11:24:24Z","timestamp":1694949864000},"page":"102421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Chronic myeloid leukaemia: A qualitative interview study exploring disease impact from patient and practitioner perspectives"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4196-0270","authenticated-orcid":false,"given":"Ann","family":"Hewison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"McCaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Patmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Atkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejon.2023.102421_bib1","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.005","article-title":"A critical history of chronic myeloid leukemia","volume":"6","author":"Baccarani","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"2","key":"10.1016\/j.ejon.2023.102421_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.2013.094045","article-title":"Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden","volume":"99","author":"Baccarani","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ejon.2023.102421_bib3","first-page":"1","article-title":"Cancer as a chronic illness: support needs and experiences","volume":"19","author":"Boele","year":"2019","journal-title":"BMJ Support. Palliat. Care"},{"issue":"3","key":"10.1016\/j.ejon.2023.102421_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/2374373517748641","article-title":"Challenges to care and medication adherence of patients with chronic myeloid leukemia in a resource limited setting: a qualitative study","volume":"5","author":"Bolarinwa","year":"2018","journal-title":"Journal of Patient Experience"},{"issue":"5","key":"10.1016\/j.ejon.2023.102421_bib5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ejh.13155","article-title":"Needs for information and reasons for (non)adherence in chronic myeloid leukaemia: Be aware of social activities disturbing daily routines","volume":"101","author":"Boons","year":"2018","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.ejon.2023.102421_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual. Res. Psychol."},{"key":"10.1016\/j.ejon.2023.102421_bib7","series-title":"Successful Qualitative Research: A Practical Guide for Beginners","author":"Braun","year":"2013"},{"issue":"10","key":"10.1016\/j.ejon.2023.102421_bib8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.leukres.2015.07.004","article-title":"Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients","volume":"39","author":"Breccia","year":"2015","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.ejon.2023.102421_bib9","article-title":"Medication adherence among patients with chronic myeloid leukemia: the impact of financial burden and psychosocial distress","volume":"8","author":"Buzaglo","year":"2017","journal-title":"Journal of Oncology Navigation and Survivorship"},{"issue":"1","key":"10.1016\/j.ejon.2023.102421_bib10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11096-013-9867-8","article-title":"Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients","volume":"36","author":"Chen","year":"2014","journal-title":"Int. J. Clin. Pharm."},{"issue":"4","key":"10.1016\/j.ejon.2023.102421_bib11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.17149","article-title":"The chronic myeloid leukaemia story in the United Kingdom since 1960","volume":"191","author":"Clark","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.ejon.2023.102421_bib12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/hex.12346","article-title":"Self-management support from the perspective of patients with a chronic condition: a thematic synthesis of qualitative studies","volume":"19","author":"Dwarswaard","year":"2016","journal-title":"Health Expect."},{"issue":"17","key":"10.1016\/j.ejon.2023.102421_bib13","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ejon.2023.102421_bib14","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-012-1458-6","article-title":"Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?","volume":"91","author":"Efficace","year":"2012","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.ejon.2023.102421_bib15","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejon.2023.102421_bib16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","article-title":"International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24","volume":"23","author":"Efficace","year":"2014","journal-title":"Qual. Life Res."},{"issue":"4","key":"10.1016\/j.ejon.2023.102421_bib17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3324\/haematol.2013.093724","article-title":"Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia","volume":"99","author":"Efficace","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ejon.2023.102421_bib18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","article-title":"The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors","volume":"2","author":"Efficace","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.ejon.2023.102421_bib19","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"Eliasson","year":"2011","journal-title":"Leuk. Res."},{"issue":"10","key":"10.1016\/j.ejon.2023.102421_bib20","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s11136-017-1611-8","article-title":"Recovering from chronic myeloid leukemia: the patients' perspective seen through the lens of narrative medicine","volume":"26","author":"Graffigna","year":"2017","journal-title":"Qual. Life Res."},{"issue":"11","key":"10.1016\/j.ejon.2023.102421_bib21","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1185\/03007995.2014.944973","article-title":"Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase","volume":"30","author":"Gu\u00e9rin","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.ejon.2023.102421_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1525822X05279903","article-title":"How many interviews are enough?: an experiment with data saturation and variability","volume":"18","author":"Guest","year":"2006","journal-title":"Field Methods"},{"issue":"2","key":"10.1016\/j.ejon.2023.102421_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40271-013-0006-3","article-title":"The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: qualitative insights using a global ethnographic approach","volume":"6","author":"Guilhot","year":"2013","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.ejon.2023.102421_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1472-6963-14-211","article-title":"The Survivor Unmet Needs Survey (SUNS) for haematological cancer survivors: a cross-sectional study assessing the relevance and psychometric properties","volume":"14","author":"Hall","year":"2014","journal-title":"BMC Health Serv. Res."},{"issue":"3","key":"10.1016\/j.ejon.2023.102421_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/bmjspcare-2012-000200","article-title":"Defining chronic cancer: patient experiences and self-management needs","volume":"2","author":"Harley","year":"2012","journal-title":"BMJ Support. Palliat. Care"},{"issue":"1","key":"10.1016\/j.ejon.2023.102421_bib26","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1136\/bmjspcare-2015-001032","article-title":"Evaluating the experiences and support needs of people living with chronic cancer: development and initial validation of the Chronic Cancer Experiences Questionnaire (CCEQ)","volume":"9","author":"Harley","year":"2019","journal-title":"BMJ Support. Palliat. Care"},{"issue":"8","key":"10.1016\/j.ejon.2023.102421_bib27","first-page":"1117","article-title":"What are the unmet supportive care needs of people with cancer? A systematic review","volume":"17","author":"Harrison","year":"2009","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ejon.2023.102421_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejon.2020.101730","article-title":"Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: a thematic synthesis of qualitative studies","volume":"45","author":"Hewison","year":"2020","journal-title":"Eur. J. Oncol. Nurs."},{"key":"10.1016\/j.ejon.2023.102421_bib29","series-title":"Managing Treatment and Living with Chronic Myeloid Leukaemia","author":"Hewison","year":"2021"},{"key":"10.1016\/j.ejon.2023.102421_bib30","series-title":"Haematological Malignancy Research Network","author":"HMRN","year":"2022"},{"issue":"4","key":"10.1016\/j.ejon.2023.102421_bib31","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejon.2023.102421_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263672","article-title":"Incurable but treatable: understanding, uncertainty and impact in chronic blood cancers\u2014a qualitative study from the UK's Haematological Malignancy Research Network","volume":"17","author":"Howell","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ejon.2023.102421_bib33","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00432-018-2594-8","article-title":"Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia","volume":"144","author":"Jiang","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ejon.2023.102421_bib34","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.pec.2019.04.028","article-title":"Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies","volume":"102","author":"LeBlanc","year":"2019","journal-title":"Patient Educ. Counsel."},{"issue":"7","key":"10.1016\/j.ejon.2023.102421_bib35","first-page":"1925","article-title":"Understanding and challenges in taking tyrosine kinase inhibitors among Malaysian chronic myeloid leukemia patients: a qualitative study","volume":"18","author":"Lim","year":"2017","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"8","key":"10.1016\/j.ejon.2023.102421_bib36","first-page":"3609","article-title":"Unmet care needs in people living with advanced cancer: a systematic review","volume":"24","author":"Moghaddam","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"5","key":"10.1016\/j.ejon.2023.102421_bib37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1177\/1049732315576699","article-title":"Data were saturated","volume":"25","author":"Morse","year":"2015","journal-title":"Qual. Health Res."},{"key":"10.1016\/j.ejon.2023.102421_bib38","doi-asserted-by":"crossref","unstructured":"Mortensen GL, Mourek J. Drivers and barriers to medication adherence in patients with chronic myeloid leukaemia: A Qualitative Study. Luiz Affonso F, editor. JHOR. 2017; 3(1): pp.1\u201315. DOI: 10.14302\/issn.2372-6601.jhor-17-1761.","DOI":"10.14302\/issn.2372-6601.jhor-17-1761"},{"key":"10.1016\/j.ejon.2023.102421_bib39","series-title":"Common Terminology Criteria for Adverse Events v5.0","year":"2017"},{"issue":"22","key":"10.1016\/j.ejon.2023.102421_bib40","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ejon.2023.102421_bib41","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","article-title":"Standards for reporting qualitative research: a synthesis of recommendations","volume":"89","author":"O'Brien","year":"2014","journal-title":"Acad. Med."},{"issue":"5","key":"10.1016\/j.ejon.2023.102421_bib42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.clml.2019.12.019","article-title":"Withdrawal syndrome after tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the Russian prospective study RU-SKI","volume":"20","author":"Petrova","year":"2020","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"4","key":"10.1016\/j.ejon.2023.102421_bib43","first-page":"1097","article-title":"Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison","volume":"21","author":"Phillips","year":"2013","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ejon.2023.102421_bib44","unstructured":"QSR International Pty Ltd. NVIVO 11 and 12 pro software 2015 [Internet] https:\/\/www.qsrinternational.com\/nvivo-qualitative-data-analysis-software\/home?_ga=2.138529779.1987834265.1654076082-1780694873.1654076082 [accessed 31st July 2023]."},{"issue":"9","key":"10.1016\/j.ejon.2023.102421_bib45","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ejon.2023.102421_bib46","series-title":"Qualitative Research Practice: a Guide for Social Science Students and Researchers","first-page":"77","article-title":"Designing and selecting samples","author":"Ritchie","year":"2003"},{"issue":"3","key":"10.1016\/j.ejon.2023.102421_bib47","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/ije\/dyab275","article-title":"Cohort profile update: the haematological malignancy research network (HMRN)\u2019s UK population-based cohorts","volume":"51","author":"Roman","year":"2022","journal-title":"Int. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.ejon.2023.102421_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyy044","article-title":"Cohort profile: the haematological malignancy research network (HMRN): a UK population-based patient cohort","volume":"47","author":"Smith","year":"2018","journal-title":"Int. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.ejon.2023.102421_bib49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.16971","article-title":"A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia","volume":"191","author":"Smith","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.ejon.2023.102421_bib50","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1177\/1359105316660179","article-title":"\u2018Haematological cancers, they\u2019re a funny bunch\u2019: a qualitative study of non-Hodgkin\u2019s lymphoma patient experiences of unmet supportive care needs","volume":"23","author":"Swash","year":"2018","journal-title":"J. Health Psychol."},{"key":"10.1016\/j.ejon.2023.102421_bib51","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2147\/PPA.S132894","article-title":"Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study","volume":"11","author":"Tan","year":"2017","journal-title":"Patient Prefer. Adherence"},{"issue":"1","key":"10.1016\/j.ejon.2023.102421_bib52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/pon.2050","article-title":"Partners and close family members of long-term cancer survivors: health status, psychosocial well-being and unmet supportive care needs","volume":"22","author":"Turner","year":"2011","journal-title":"Psycho Oncol."},{"issue":"1\u20132","key":"10.1016\/j.ejon.2023.102421_bib53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jocn.13775","article-title":"The role of the family in supporting the self-management of chronic conditions: a qualitative systematic review","volume":"27","author":"Whitehead","year":"2018","journal-title":"J. Clin. Nurs."},{"issue":"5","key":"10.1016\/j.ejon.2023.102421_bib54","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","article-title":"Measuring the symptom burden associated with the treatment of chronic myeloid leukemia","volume":"122","author":"Williams","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejon.2023.102421_bib55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1017\/S1478951513001260","article-title":"Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: a qualitative study","volume":"13","author":"Wu","year":"2015","journal-title":"Palliat. Support Care"},{"issue":"Suppl. 1","key":"10.1016\/j.ejon.2023.102421_bib56","first-page":"4704","article-title":"Symptom burden, palliative care needs, and patient-provider communication among chronic myeloid leukemia survivors","volume":"130","author":"Zaleta","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejon.2023.102421_bib57","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1002\/cam4.1808","article-title":"A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors","volume":"7","author":"Zulbaran\u2010Rojas","year":"2018","journal-title":"Cancer Med."}],"container-title":["European Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388923001552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388923001552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T20:25:35Z","timestamp":1761423935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1462388923001552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":57,"alternative-id":["S1462388923001552"],"URL":"https:\/\/doi.org\/10.1016\/j.ejon.2023.102421","relation":{},"ISSN":["1462-3889"],"issn-type":[{"value":"1462-3889","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic myeloid leukaemia: A qualitative interview study exploring disease impact from patient and practitioner perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejon.2023.102421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102421"}}